Royalty Pharma PLC at Truist Securities Life Sciences Summit (Virtual) Transcript
Everyone, I am Gregg Gilbert and I cover pharmaceuticals here at Truist. I'm fortunate to be hosting this fireside session, although it's a little warm today for a fire, but we're still going to call it that. And it's with Royalty Pharma management.
Before we begin, I need to read the following disclaimer. This call is arranged by Truist Securities research, released by institutional investors and issuer clients as defined by FINRA. If you are not an institutional investor or issuer, please disconnect at this time. For our required disclosures, please see our website at truistsecurities.com or our equity research library.
On today's session, we have with us Terry Coyne, CFO; Chris Hite, Vice Chairman; Jim Reddoch; Co-Head of Research and Investments and Chief Scientific Officer; and George Grofik, Head of Investor Relations. Thank you, gentlemen, so much for joining me and the firm. And thank you also to our Truist investor clients that are watching, listening now or reading later.
Terry will start with
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |